艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

盘前交易 03-20 05:36:54 EDT

78.67

-0.40

-0.51%

盘前79.14

+0.47+0.60%

04:10 EDT

最高79.70	最低78.46	成交量85.62万
今开79.20	昨收79.07	日振幅1.56%
总市值94.43亿	流通市值85.25亿	总股本1.20亿
成交额6,748万	换手率0.79%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":78.67,"timestamp":1773950400000,"preClose":79.07,"halted":0,"volume":856198,"hourTrading":{"tag":"盘前","latestPrice":79.14,"preClose":78.67,"latestTime":"04:10 EDT","volume":30,"amount":2376.9198,"timestamp":1773994223780,"change":0.47,"changeRate":0.005974,"amplitude":0.008644},"delay":0,"changeRate":-0.005058808650562685,"floatShares":108366822,"shares":120028300,"eps":1.77,"marketStatus":"盘前交易","change":-0.4,"latestTime":"03-20 05:36:54 EDT","open":79.2,"high":79.695,"low":78.46,"amount":67478736.70986001,"amplitude":0.015619,"askPrice":87.25,"askSize":1,"bidPrice":76.1,"bidSize":38,"shortable":3,"etf":0,"ttmEps":1.77,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774013400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":78.67,"dividendRate":0.039164,"preHourTrading":{"tag":"盘前","latestPrice":79.14,"preClose":78.67,"latestTime":"04:10 EDT","volume":30,"amount":2376.9198,"timestamp":1773994223780,"change":0.47,"changeRate":0.005974,"amplitude":0.008644},"postHourTrading":{"tag":"盘后","latestPrice":78.67,"preClose":78.67,"latestTime":"17:57 EDT","volume":83849,"amount":6596401.35,"timestamp":1773957458913,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6878212772992569,"impliedVol":0.2276,"impliedVolPercentile":0.652},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2616318725","title":"百利天恒：自研ADC药物注射用BL-M11D1获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2616318725","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616318725?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:46","pubTimestamp":1772621169,"startTime":"0","endTime":"0","summary":"3月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M11D1（CD33-ADC）的药物临床试验获得批准。BL-M11D1是与iza-bren出自同一技术平台、与iza-bren共享同一“连接子+毒素”平台的靶向CD33的ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661878918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","LU1815336091.USD","BL","BK0239","LU0757428866.USD","BK4023","BK4080","688506","91194","BK4231","ADC"],"gpt_icon":0},{"id":"2616370344","title":"诺诚健华：首个自主研发的B7H3靶向ADC候选药正在入组患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2616370344","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616370344?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:30","pubTimestamp":1772537441,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华（688428.SH）3月3日在投资者互动平台表示，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿元左右。公司对于未来包括奥布替尼在内的药品销售、管线进展及商业化合作充满信心。更重要的是，公司的增长逻辑并非依赖单一产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603033660525335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603033660525335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","09969","688428","BK1574","BK4080","BK4231","BK1161","BK0239"],"gpt_icon":0},{"id":"2613713953","title":"百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713953","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713953?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:39","pubTimestamp":1771933190,"startTime":"0","endTime":"0","summary":"2月23日，百利天恒（SH688506，股价289.59元，市值1195.6亿元）宣布其自主研发的全球首创EGFR×HER3双抗ADC药物（抗体偶联药物）iza-bren，在针对局部晚期或转移性三阴性乳腺癌（TNBC）的Ⅲ期临床试验中取得突破。期中分析数据显示，该药物显著延长了患者的无进展生存期（PFS）和总生存期（OS），达到双主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652920641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652920641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK4080","91194","02615","BK0239","BK4231","ADC"],"gpt_icon":0},{"id":"2613820071","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2613820071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613820071?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 披露公告，关于iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4134","III","91194","BK4080","ADC","BK4231","688506","02615"],"gpt_icon":0},{"id":"2610616389","title":"西南证券：驱动基因阴性NSCLC市场空间广阔 双(多)抗、IO+ADC方案齐头并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2610616389","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610616389?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:50","pubTimestamp":1770706257,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，目前一线治疗驱动基因阴性NSCLC晚期患者主要依赖PD-1±化疗的治疗方案，测算2030年用于驱动基因阴性NSCLC晚期一线治疗的免疫用药中美市场规模分别约为75亿元、180亿元。NSCLC下一代免疫治疗方案齐头并进，为双(多)抗以及IO+ADC。西南证券主要观点如下：驱动基因阴性空间几何?驱动基因阴性指肿瘤样本中未检测到明确可靶向的驱动基因突变，分别占中美患者新发NSCLC患者的31%/31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600369","BK4231","ADC","BK4080","BK0183","BK0012","BK0028","BK0188","BK0276"],"gpt_icon":0},{"id":"2610661036","title":"中国生物制药(01177)：TQB2102“HER2双抗ADC”HER2低表达乳腺癌III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661036","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610661036?lang=zh_cn&edition=full","pubTime":"2026-02-10 06:16","pubTimestamp":1770675411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验”，近期已完成全部受试者入组。以上核心技术的结合，突破了传统HER2单抗及单靶点ADC的局限，使TQB2102在HER2低表达肿瘤治疗中展现出显著潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","HK0000165453.HKD","BK4080","IE00BZ08YR35.GBP","ADC","01177","BK4231","BK1521","BK4134","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","III","BK1515","BK1589"],"gpt_icon":0},{"id":"2610502918","title":"港股异动 | 石药集团(01093)涨超3% 机构看好公司未来在EGFR ADC及研发平台将有更多对外授权合作机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2610502918","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610502918?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:35","pubTimestamp":1770604509,"startTime":"0","endTime":"0","summary":"消息面上，汇丰研究发布研究报告指出，石药集团股价年初至今累计上涨约9%，在1月30日公布与阿斯利康的合作前已升14%，目前认为其估值仍然吸引，并憧憬未来在EGFR ADC及研发平台将有更多对外授权合作机会，计及预付款及上季销售轻微改善的预期，将2025至2027年收入预测上调3%至11%。该行并将石药集团2025至2027年净利润预测上调7%至18%，认为对外授权收入的增长已能抵销药品集中带量采购政策所带来的负面影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","LU0072913022.USD","LU1152091754.HKD","LU1951186391.HKD","BK1515","LU1960683339.HKD","BK1521","LU1008478684.HKD","IE00BZ08YS42.EUR","LU0501845795.SGD","LU1152091168.USD","LU0315179316.USD","LU0140636845.USD","LU1226288253.USD","LU1328277881.USD","VXUS","VT","LU0067412154.USD","BK1191","LU1226287875.USD","BK4585","IE00B031HY20.USD","SG9999004220.SGD","HK0000165453.HKD","IE0008368742.USD","LU2039709279.SGD","LU1993786604.SGD","LU0314109678.HKD","LU1226287529.USD","IE00B5MMRT66.SGD","BK4588","IE00BZ08YT58.USD","LU1807302812.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","01093","IE0008369823.USD","BK4231","LU1813983027.USD","BK4080","LU1226287792.SGD","ADC","LU0880133367.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2610503880","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610503880","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610503880?lang=zh_cn&edition=full","pubTime":"2026-02-09 06:15","pubTimestamp":1770588951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药维特柯妥拜单抗“CLDN18.2 ADC”正在开展用于治疗三线及以上CLDN18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌的III期注册临床试验，已顺利完成患者入组。其中，LM302是全球首款完成注册III期临床试验入组的CLDN18.2 ADC药物。该研究表明，LM302联合治疗方案在CLDN18.2阳性患者中展现出显著的抗肿瘤活性和可管理的安全性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","IE00BZ08YR35.GBP","III","BK4080","IE00BZ08YT58.USD","BK1191","01177","BK4134","BK4231","IE00BZ08YS42.EUR","ADC","BK1515","BK1589","HK0000165453.HKD"],"gpt_icon":0},{"id":"1132811598","title":"Pyxis Oncology宣布临时CEO任命及领导层交接，聚焦战略重点与项目延续性","url":"https://stock-news.laohu8.com/highlight/detail?id=1132811598","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132811598?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:49","pubTimestamp":1770119377,"startTime":"0","endTime":"0","summary":"波士顿，2026年2月3日——临床阶段生物制药公司Pyxis Oncology, Inc.今日宣布领导层交接计划，旨在持续推进公司战略与临床目标的执行。自公司首次公开募股以来一直担任董事会成员的Thomas Civik被任命为临时首席执行官，即刻生效。通过此次人事调整，Pyxis Oncology将由深度熟悉公司战略及研发项目的资深领导者掌舵。董事会主席John Flavin表示：\"任命Tom为临时CEO是为了确保领导力的稳健过渡与业务连续性。Pyxis Oncology已奠定坚实的科研与临床基础，我们对核心项目的前景保持乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4022","BK4231","R","LU0210528500.USD","BK4107","ADC","LU2487616109.SGD","BK4585","BK4080","BK4232","LU0053666078.USD","BK4139","PYXS","L"],"gpt_icon":0},{"id":"1131684922","title":"财报前瞻｜艾格里房产本季度营收预计增18.63%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1131684922","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131684922?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:33","pubTimestamp":1770086001,"startTime":"0","endTime":"0","summary":"艾格里房产将在2026年02月10日发布最新季度财报，市场关注其租金收入增长与利润率表现，以及管理层对净利润和EPS的指引与执行力。市场一致预期显示，本季度艾格里房产总收入预计为1.86亿美元，同比增长18.63%；毛利率预计维持高位但未给出具体预测值；净利润或净利率本季度未形成明确一致预期；调整后每股收益预计为0.47美元，同比增长9.77%；EBIT预计为9,678.30万美元，同比增速26.16%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜艾格里房产本季度营收预计增18.63%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC"],"gpt_icon":0},{"id":"2606376243","title":"东方证券：IO和ADC为肿瘤头部MNC焦点 联用将迎突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2606376243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606376243?lang=zh_cn&edition=full","pubTime":"2026-01-28 14:13","pubTimestamp":1769580821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，JPM 2026大会上肿瘤领域头部MNC将IO和ADC作为战略重心，且十分重视联合疗法的开发，其中二代IO多来自国产企业，sac-TMT在ADC中地位突出，今年是IO联合ADC确定性提升的关键节点，未来ADC尤其是泛瘤种ADC的需求有望进一步提升。另一方面，围绕IO和ADC的联用探索正全面加速，默沙东已开展9项sac-TMT联用K药的III期临床研究，BMS将推进BNT327与ADC的联用，辉瑞计划今年开展SSGJ-707和ADC联用的III期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03958","600958","BK1564","BK0012","BK4080","BK0276","BK0028","BK0183","BK1147","BK4231","ADC"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605989254?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4211","BK4195","BK4231","OS","ADC","ORR","PFS","BK4097","BK4080"],"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0234572021.USD","LU1571399168.USD","BK4588","LU0320765992.SGD","BK4231","LU0792757196.USD","LU1929549753.HKD","BK4097","LU2237443895.HKD","LU2237443622.USD","ADC","LU1046421795.USD","LU1221951046.USD","BK4612","LU1244550577.SGD","LU1880398554.USD","LU2506951875.HKD","LU2506951958.HKD","BK4080","LU0109394709.USD","IE00BKVL7J92.USD","LU0868494617.USD","LU1066053197.SGD","BK4560","CSCO","IE00BFMHRM44.USD","IE000M9KFDE8.USD","SG9999015978.USD","BK4195","LU2417539215.USD","LU1196500208.SGD","LU1894683348.USD","LU2237443549.SGD","LU1244550494.USD","SG9999015945.SGD","LU2247934214.USD","LU1221951129.SGD","BK4579","BK4585","LU1066051498.USD","AZN","LU1880398471.USD","LU2237443382.USD","LU2462157665.USD","ORR","OS","PFS","LU2506952097.USD","SG9999001440.SGD","BK4527"],"gpt_icon":0},{"id":"2605696344","title":"优赫得在华获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2605696344","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605696344?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:46","pubTimestamp":1769071572,"startTime":"0","endTime":"0","summary":"南方财经1月22日电，记者获悉，由阿斯利康和第一三共共同开发与商业化的优赫得?（英文商品名：Enhertu?，通用名：注射用德曲妥珠单抗）获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627420221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2605667194","title":"华福证券：首次覆盖维立志博(09887)给予“买入”评级 下一代IO和ADC疗法全布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2605667194","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605667194?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:38","pubTimestamp":1769067529,"startTime":"0","endTime":"0","summary":"首次覆盖维立志博给予“买入”评级，预计维立志博2025-2027年营业收入分别为1.80、0.94、0.10亿元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260122/20260122154150_41671.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09887","ADC","161027"],"gpt_icon":0},{"id":"2604157635","title":"港股异动 | 映恩生物-B(09606)早盘涨超4% ADAM9靶向ADC癌症新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2604157635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604157635?lang=zh_cn&edition=full","pubTime":"2026-01-20 09:48","pubTimestamp":1768873737,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B早盘涨超4%，截至发稿，涨2.42%，报363.6港元，成交额5105.75万港元。消息面上，1月19日，映恩生物宣布，公司自主研发的ADAM9靶向抗体偶联药物DB-1317已获得国家药监局药品审评中心的新药临床试验批准，同意其单药在晚期/转移性恶性实体瘤患者中开展临床试验。据悉，DB-1317是映恩生物基于公司自主研发的ADC技术平台DITAC开发的新一代ADC产品，具有全球权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","BK4080","BK1161","BK4231","HK0000252160.HKD","09606","HK0000500386.USD","LU2543165471.USD","ADC"],"gpt_icon":0},{"id":"2603603977","title":"跨国巨头艾伯维锚定本土创新，全球资源如何加速落地中国？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603977","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603977?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:33","pubTimestamp":1768469598,"startTime":"0","endTime":"0","summary":"三生制药将一款处于临床阶段的双特异性抗体药物以60.5亿美元的价格授权给辉瑞；恒瑞医药与葛兰素史克（GSK）达成潜在价值125亿美元的交易；信达生物与武田制药就三款产品达成114亿美元的交易……当下，中国生物医药行业的交易纪录正被本土创新力量持续刷新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620504655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620504655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","GSK","GSK.UK","BK4080","BK4588","BK4231","LU1829250122.USD","ADC","BK4585","BK4532"],"gpt_icon":0},{"id":"2603867929","title":"31亿港元！药明合联拟溢价99%收购东曜药业，ADC产能有望进一步拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603867929","media":"澎湃新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603867929?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:13","pubTimestamp":1768461189,"startTime":"0","endTime":"0","summary":"国内CXO行业再现大手笔收购。1月14日晚间，药明生物（2269.HK）、药明生物附属公司药明合联（2268.HK）及东曜药业（1875.HK）发布联合公告称，药明合联通过财务顾问花旗环球金融亚洲有限公司，向东曜药业发出自愿有条件现金要约，拟收购其全部已发行股份（要约人及一致行动人士已持有或同意收购的股份除外），并注销全部尚未行使购股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620361651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620361651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","02268","LU2488822045.USD","BK4231","SG9999014674.SGD","BK1141","BK4080"],"gpt_icon":0},{"id":"2603610556","title":"业绩盈喜, 控股收购东曜药业，药明合联(02268)进一步稳固ADC CDMO市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2603610556","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603610556?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:32","pubTimestamp":1768404738,"startTime":"0","endTime":"0","summary":"同时，通过此次控股收购，药明合联亦希望进一步丰富其项目组合并扩大其客户群，稳固其在 ADC CDMO 领域的领导地位。药明合联早已布局人才梯队建设，截至2025年底，团队规模已突破2600人。截至2025年12月底，药明合联在全球合作客户数量已超过630家，iCMC项目总数达到252个。这一举措不仅能实现产能的本地化交付，更能进一步深化公司在全球生物偶联药CDMO领域的市场覆盖，巩固行业领先地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1141","ADC","CDMO","BK4139","SG9999014674.SGD","02268","LU2488822045.USD","BK4080"],"gpt_icon":1},{"id":"2603550770","title":"岁末年初，药企高管缘何密集迎人事变动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603550770","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603550770?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:00","pubTimestamp":1768298423,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明离职恒瑞医药（600276.SH）四年多后，周云曙的新任职动态浮出水面。日前，“江苏省肿瘤医院官方平台”发布消息显示，江苏省肿瘤医院（南京医科大学附属肿瘤医院）“江苏省恶性肿瘤先进诊疗重点实验室”与先声药业“神经与肿瘤药物研发全国重点实验室”正式签署战略合作协议，周云曙以“先声药业集团总裁”身份出席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617514380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617514380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU1580142542.USD","LU2097828714.EUR","LU2097828474.EUR","LU1655091616.SGD","LU2097828631.EUR","BK1161","LU1146622755.USD","LU0405327148.USD","LU0359202008.SGD","LU2289578879.USD","LU0359201612.USD","LU2148510915.USD","LU1328615791.USD","BK0239","LU2580892789.USD","LU2543165471.USD","LU2488822045.USD","LU2328871848.SGD","LU1997245094.SGD","LU1820825898.SGD","BK0183","BK0188","LU2097828805.USD","LU2495084118.USD","BK0012","BK1583","LU1064130708.USD","BK1574","BK4231","LU1997245177.USD","BK0196","BK0028","BK1191","LU2580892862.HKD","06978","LU2097828557.USD","LU1064131003.USD","BK0060","02096","600276","LU1781817850.SGD","LU1969619763.USD","LU1255011170.USD","01276","ADC","LU1997244956.HKD","LU0405327494.USD","BK4080"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0124},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0911},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.035},{"period":"ytd","weight":0.0922}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.014109},{"month":4,"riseRate":0.580645,"avgChangeRate":0.002795},{"month":5,"riseRate":0.5,"avgChangeRate":0.015633},{"month":6,"riseRate":0.65625,"avgChangeRate":0.010123},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}